BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

GlaxoSmithKline (GSK) to Buy $129.4M in Theravance, Inc. (THRX) Stock


11/29/2010 7:45:08 AM

San Francisco Business Times - by John Sailors -- GlaxoSmithKline PLC will buy about $129.4 million worth of stock in Theravance Inc. in a private placement, the companies said Monday.

London-based Glaxo (NYSE: GSK) agreed to buy 5.75 million shares for $22.50 each.

The purchase increases Glaxo's stake in South San Francisco-based Theravance (NASDAQ: THRX) to 19 percent.

The transaction is expected to close today.

Theravance is working with Glaxo to develop Relovair, an asthma treatment. The two companies began collaborating on the drug in 2002.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->